The concept of PLGA-lipid hybrid nanoparticles arose as a motivation for developing drug
delivery systems with versatile physical and chemical properties, unequivocal therapeutic …

Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer,
ranks among the leading causes of cancer-related deaths in the Western world due to …

Cancer is a leading cause of death in many countries around the world. However, the
efficacy of current standard treatments for a variety of cancers is suboptimal. First, most …

Cancer nanotherapeutics are progressing at a steady rate; research and development in the
field has experienced an exponential growth since early 2000's. The path to the …

Combination chemotherapy is widely exploited for enhanced cancer treatment in the clinic.
However, the traditional cocktail administration of combination regimens often suffers from …

Nanoparticles can preferentially accumulate at sites of action and hold great promise to
improve the therapeutic index of many drugs. While conventional methods of nanocarrier …

Most of the dual nano drug delivery systems fail to enter malignant brain tumors due to a
lack of proper targeting systems and the size increase of the nanoparticles after drug …

Medical diagnosis and therapy are essential for providing patients with proper care,
although inefficient diagnosis and therapy are usually associated with either improper …

Lipid–polymer hybrid nanoparticles (LPHNPs) are next-generation core–shell
nanostructures, conceptually derived from both liposome and polymeric nanoparticles …

Lipid–polymer hybrid nanoparticles (LPNs) are core–shell nanoparticle structures
comprising polymer cores and lipid/lipid–PEG shells, which exhibit complementary …